Takeda Korea's Kynteles SC wins insurance benefit

1 December 2022 - Takeda Pharmaceuticals Korea said Kynteles SC, an inflammatory bowel disease treatment, started to be covered by ...

Read more →

'Reimbursement criteria for CGRP inhibiting migraine drugs not realistic'

28 November 2022 - The CGRP (calcitonin gene-related peptide) inhibitors, developed to prevent adult migraines, have recently been registered on ...

Read more →

MSD's Zerbaxa becomes Korea's newest antibiotic to receive reimbursement

27 October 2022 - MSD Korea is strengthening its position in the local antibiotic market with Zerbaxa (ingredient: ceftolozane/tazobactam) after ...

Read more →

‘Current standard for stopping insurance benefits for SMA treatment harsh on adult patients’

12 October 2022 - Spinraza (nusinersen sodium), the first spinal muscular atrophy treatment that won the insurance coverage quickly since ...

Read more →

Janssen's Imbruvica passes reimbursement review, BeiGene's Brukinsa fails

22 September 2022 - Janssen's Imbruvica (ibrutinib) and BeiGene's Brukinsa (zanubrutinib), the two BTK (Bruton tyrosine kinase) inhibitors with the ...

Read more →

Health movement in South Korea fights for universal access to medicines

10 September 2022 - Civil society in South Korea renewed its commitment to ensure universal access to medicines and public pharmaceutical ...

Read more →

Janssen's Stelara gets insurance benefits as first-line therapy for ulcerative colitis

1 September 2022 - Janssen Korea said its ulcerative colitis Stelara (ustekinumab) won health insurance benefits as the primary treatment ...

Read more →

Amgen's acute lymphoblastic leukaemia drug Blincyto passes reimbursement review

11 August 2022 - Amgen's acute lymphoblastic leukaemia treatment Blincyto (blinatumomab) passed the reimbursement review about two years after expanding ...

Read more →

Delay of Evrysdi reimbursement review denies SMA patients' right to drug choice

2 August 2022 - The Government has been dragging its feet to review insurance benefits for Roche's new spinal muscular ...

Read more →

Korea's first gene treatment for SMA Zolgensma gets insurance benefits

2 August 2022 - Novartis Korea said Monday that it released Zolgensma, the nation's first gene replacement treatment for spinal ...

Read more →

Ultra-expensive SMA drug Zolgensma to get insurance benefits from August

21 July 2022 - Novartis' Zolgensma (onasemnogene abeparvovec), the world's most expensive drug yet to treat spinal muscular atrophy, will ...

Read more →

'Government excessively controls drug prices, not recognising novel drugs' value'

15 July 2022 - The Government is wielding excessive power to lower drug prices without recognising the values ​​of innovative ...

Read more →

Celltrion Pharm's liver disease drug may lose insurance benefits

8 July 2022 - Celltrion's prescription liver disease treatment Godex might lose reimbursement because the HIRA recently decided to withdraw ...

Read more →

Revlimid maintenance therapy passes reimbursement review

30 June 2022 - Revlimid maintenance therapy to treat multiple myeloma passed the health insurance review agency’s reimbursement review four ...

Read more →

Reimbursement price of GERD drug Fexclu finalised at $0.73

29 June 2022 - The Ministry of Health and Welfare’s health insurance policy committee set the reimbursement price of Fexclu ...

Read more →